MREO:NASDAQMereo BioPharma Group plc analysis
Data as of Sep 1, 2026 - not real-time
- Latest price
- $0.27
- Risk: high
- 9/10High risk
Summary
At $0.2668, Mereo BioPharma Group plc shows a bearish moving-average alignment, with shorter averages beneath longer ones. The last 30 days have lost 12.5%. Relative strength is 39.6 — approaching oversold — and the MACD signal is bearish. Recent trading has carved out support near $0.2520 and resistance around $0.3700.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 650.1% above where the shares trade now.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 72.7%, a beta of 1.50 and a maximum drawdown of 89.7%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
This one splits by horizon — sell in the near term, hold further out, at 1/10 long-term conviction.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 650.1% above where the shares trade now.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 72.7%, a beta of 1.50 and a maximum drawdown of 89.7%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
This one splits by horizon — sell in the near term, hold further out, at 1/10 long-term conviction.
Top market events
- Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo’s investigational oral...
- Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo's investigational oral...
- Sentynl Therapeutics, Inc. "Sentynl" , a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus...
Market outlook
Short term
< 1 yearCautious
Model confidence4/104 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 0.60
- MACD momentum is negative
Medium term
1–3 yearsNeutral
Model confidence2/102 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 0.60
- Analyst targets imply +650.1% versus the current price
Long term
> 3 yearsNeutral
Model confidence1/101 out of 10
Key factors
- Analyst targets imply +650.1% versus the current price
- Negative return on equity of -67.8%
- Negative free cash flow
Key metrics
Financial health
P/E Ratio-11.4
ROE-67.85%
ROA-42.46%
Debt/Equity3.60
P/B Ratio1.5
Op. Cash Flow$-25346000
Free Cash Flow$-13656500
Industry P/E30.4
Technical analysis
TrendBearish
RSI39.6
Support$0.25
Resistance$0.37
MA 20$0.29
MA 50$0.31
MA 200$0.60
MACDBearish
VolumeDecreasing
Fear & Greed Index94.79
Valuation
Target Price$2.00
Upside/Downside650.10%
GradeFair
TypeBlend
Risk assessment
Beta1.50
Volatility72.66%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar tickers
DNMX
Dynamix Corporation III
stockZENA
ZenaTech, Inc.
stockZBIO
Zenas BioPharma, Inc.
stockABCL
AbCellera Biologics Inc.
stockWTFCN
Wintrust Financial Corporation - Depositary Shares, Each Representing a 1/1,000th Interest in a Share of 7.875% Fixed-Rate Reset Non-Cumulative Perpetual Prefer
stockWSTN
Westin Acquisition Corp
stockThis analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.